To evaluate the clinical efficacy of Lushi Runzao Decoction in the treatment of xerostomia in primary Sjogren syndrome. Methods: A total of 84 patients with primary drying syndrome of dual deficiency of qi and yin and blood stasis syndrome from January 2015 to January 2016 in our hospital were selected as research objects. They were randomly divided into the treatment group (42 cases) and control group (42 cases) by computer method. Treatment group were given oral Lushi Runzao Decoction, the control group was given oral sulfate hydroxychloroquine treatment. The clinical efficacy of the two groups, serological indexes and and adverse reaction before and after the treatment were compared. Results: After treatment, the the effective rate of the treatment group and the control group were 97.62% and 85.71% respectively, the difference was statistically significant (P<0.05). After treatment, salivary flow rate, dry mouth symptoms, VAS score and Chinese medicine syndromes of the patients in both group improved significantly, but the treatment group had significantly better results (P<0.05). After treatment, the serum RF, ESR and CRP of patients dropped significantly in both groups after the treatment, but the treatment group decreased more obviously (P<0.05). Conclusion: Lushi Runzao Decoction has good efficacy in the treatment of xerostomia in primary Sjogren syndrome, with good improvement in VAS score, salivary flow rate and Chinese medicine syndromes, as well as serum RF, ESR and CRP levels, which is worthy of clinical application.